New products from Eli Lilly
Eli Lilly (LLY) has launched various products under different franchises. A few of these new products include Portrazza, Cyramza, Basaglar, Jardiance, Taltz, and Trulicity.
Basaglar is an insulin glargine injection used to control blood sugar levels in patients with both type 1 and type 2 diabetes. Basaglar is expected to be launched in the US market in December 2016. Eli Lilly reported Basaglar sales of $86.1 million in Japan and a few European markets in 2016.
Cyramza is an oncology drug used in combination with other drugs for the treatment of metastatic NSCLC (non-small cell lung cancer), advanced gastric cancer, and metastatic colorectal cancer.
Sales for Cyramza rose over 60% to $614.1 million in 2016 due to increased demand in the Japanese and European markets for the treatment of metastatic NSCLC and metastatic colorectal cancer.
Jardiance is another drug used to lower blood sugar levels in patients with type 2 diabetes. Jardiance is part of Boehringer Ingelheim and LLY’s diabetes alliance. It reported revenue of $201.9 million in 2016, compared to $60.2 million in 2015, mainly driven by increased sales in the US market.
Lartruvo is a drug used in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The drug was launched in the US and European markets in 4Q16, and it reported revenue of $11.9 million in 2016.
Portrazza is a new drug used for the treatment of metastatic squamous NSCLC. Portrazza reported sales of $14.8 million in 2016.
Other drugs in the oncology space include Pfizer’s (PFE) Inlyta and Sutent, Bristol-Myers Squibb’s (BMY) Opdivo, Merck & Co.’s (MRK) Keytruda, GlaxoSmithKline’s (GSK) Mekinist and Tafinlar, and Roche Holding’s Zelboraf.
LLY launched Taltz in the US market in April 2016, and it launched Taltz in European markets in July 2016. In 2016, Taltz’s revenue was $113.1 million, which consisted of $110.8 million in sales from the US market.
Trulicity is a drug used to improve the blood sugar levels of patients with type 2 diabetes. Trulicity reported sales of $925.5 million in 2016, compared to $248.7 million in 2015. The rise was mainly due to higher demand in the US market, where the drug reported sales of $737.6 million in the year.
To divest risk, investors can consider ETFs such as the iShares S&P Global Healthcare ETF (IXJ), which holds ~1.9% of its total assets in Eli Lilly.